FDA 2026 Food Guidance Agenda Flags Labeling and Claims Priorities

For finished-product manufacturers, the FDA’s latest Human Foods Program guidance agenda highlights near-term areas where labeling, claims substantiation, and facility registration practices may require closer regulatory attention.¹

The FDA’s Human Foods Program has released its updated 2026 guidance agenda, identifying several areas of potential relevance to finished-product manufacturers, including companies operating in the nutraceutical, functional food, and beverage sectors. The agenda includes possible new guidance topics and revisions to existing guidance documents that the agency is considering for completion during 2026.

The agenda is not a new regulation, but it provides an early view into FDA priorities that may influence compliance planning, labeling review, claims strategy, and facility registration practices. As the FDA stated in the constituent update, “Guidance documents represent the FDA’s current thinking on a specific topic, and the information in them can help stakeholders.”

What Does the FDA’s 2026 Human Foods Guidance Agenda Include?

The new topics listed by the FDA include “Labeling Caffeine Content in Foods and Beverages; Draft Guidance for Industry,” “Questions and Answers Regarding Use of the ‘Healthy’ Claim,” and “Necessity of the Use of Food Product Categories in Food Facility Registrations and Updates to Food Product Categories: Guidance for Industry.”

For companies developing finished products, these topics intersect with common commercial and regulatory decision points. Caffeine labeling may be particularly relevant for energy beverages, functional shots, powders, and other food or beverage formats that include added caffeine. Guidance on food product categories may also affect how facilities classify products in registration systems, with operational implications for firms that manufacture multiple product types.

The immediate limitation is that the FDA has released an agenda, not the underlying draft guidance documents. The agenda identifies topics under consideration, but it does not provide proposed recommendations, compliance timelines, enforcement policies, or technical criteria for caffeine labeling, “healthy” claims, or facility registration categories. The agency also added, “We may also issue additional guidance that is not on the list.”

These guidance topics, as well as several others, are listed in the FDA’s Foods Program Guidance Under Development, with a statement suggesting the guidance topics presented are expected to be published as drafts or finals by the end of December 2026.²

Why Are Caffeine Labeling and “Healthy” Claims Important for Finished Products?

The inclusion of caffeine labeling as a draft guidance topic is notable because caffeine-containing products have expanded across beverage and food formats. For manufacturers, the practical question is how the FDA may frame expectations regarding the disclosure of caffeine content, particularly where products are marketed for energy, focus, or performance-related use.

The planned question-and-answer guidance on the “healthy” claim may also be relevant for brands using nutrient-based positioning. Claims involving healthfulness can carry both marketing value and regulatory risk, particularly when used prominently on product labels or in consumer-facing materials. A question-and-answer format may help clarify the FDA’s interpretation of claim use, but the scope will depend on the draft or final document when issued.

The third new topic, involving food product categories in facility registrations, may be less visible to consumers but important for compliance teams. Facility registration data can affect how the FDA organizes information about the food supply and prioritizes oversight.

What Are the Next Steps for Industry Stakeholders?

Stakeholders can submit comments on the list of human food and cosmetic guidance topics, including alternatives or recommendations, through regulations.gov using Docket FDA-2022-D-2088. For finished product manufacturers, the comment process offers an opportunity to flag implementation concerns, category-specific issues, and areas where FDA clarification could reduce inconsistent interpretation.

References

1. FDA releases 2026 Human Foods Program guidance agenda. FDA. June 29, 2026. Accessed June 30, 2026. https://www.fda.gov/food/hfp-constituent-updates/fda-releases-2026-human-foods-program-guidance-agenda
2. Foods Program guidance under development. FDA. June 29, 2026. Accessed June 30, 2026. https://www.fda.gov/food/guidance-documents-regulatory-information-topic-food-and-dietary-supplements/foods-program-guidance-under-development